Sales +14% Jan – Mar 2014

For the January-March period

  ·
Net sales for the period were SEK 30.6 million (26.8).

  ·
Operating income (EBIT) for the period was SEK 4.2 million (2.0).

  ·
Operating margin for the period was 13 percent (7).

  ·
Earnings after tax for the period totaled SEK 1.3 million (-0.1).

  ·
Earnings per share for the period, basic and diluted, was SEK 0.01 (0.00).

President and CEO Anders Karlsson's commentary on the first quarter 2014:

“The first quarter saw continued strong growth in the U.S., as well as a clear
improvement in sales in Europe compared to the same period last year. In
countries in Europe where demand was relatively slow in 2013, it is pleasing to
see that things have started to take off again. Sales are up across the board
for our entire product range, with a key element being the ongoing introduction
of SBT Resolver™ from our partner Conexio Genomics. Naturally we are also
delighted with the improvement in our operating margin.”

For more information please contact:
Anders Karlsson, CEO Allenex AB, ph: +4670-918 00 10, e-mail:
 (anders.karlsson@allenex.se)anders.karlsson@allenex.se (anders.karlsson@allenex
. 
se)
Yvonne Axelsson, CFO Allenex AB, ph: +468-508 939 72, e-mail:
 (anders.karlsson@allenex.se)yvonne.axelsson@allenex.se

Allenex AB discloses the information provided herein pursuant to the Securities
Markets Act and /or the Financial Instruments Trading Act. The information was
submitted for publication on April 29, 2014, at 08.30 CET. Allenex is a life
science-company that develops, manufacture, market and sell products for safer
transplants of organs and bone marrow on the global market. Allenex is listed on
NASDAQ OMX Stockholm Small Cap (ticker: ALNX). 55 persons are employed in the
Allenex group.